News from 2015
Alliance Pharma acquires Healthcare Products from Sinclair IS Pharma plc
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, has announced that the acquisition of the Healthcare Products Business from Sinclair IS Pharma plc, and the placing to part fund this acquisition, have completed.
Amgen Announces FDA Approval of BioVex Drug Imlygic
The US FDA approved Imlygic for sale on 27 October 2015 and, in addition, the European regulator (CHMP) recommended on 23 October 2015 that Imlygic be approved by the European Commission.
Cara Therapeutics Announces Positive Results from Phase II Trial
Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to selectively target peripheral kappa opioid receptors, has announced statistically significant results from its Phase II trial of its lead kappa opioid agonist, CR845, for the treatment of moderate to severe uremic pruritus.
MVM sells Vascular Pathways Group of Companies
MVM sold the Vascular Pathways Group of Companies (Vascular Pathways, Inc. and Vascular Pathways Europe, Ltd.) to C.R. Bard on July 1, 2015. The transaction provides C.R. Bard with a best-in-class portfolio of peripheral vascular access technologies.
Onbone Oy raises €10m from international investor syndicate
Onbone Oy raises €10m from international investor syndicate for the global launch of its novel casting/splinting products.
AccuVein Signs Exclusive Distribution Agreement with SinoPharma-UMD in China
AccuVein Inc., have announced that they have signed an exclusive distribution agreement with SinoPharm-UMD to sell the award-winning AccuVein AV400 vein visualization device in China. The China Food and Drug Administration (CFDA) has recently approved the sale of the AccuVein AV400 in China.
Heptares Therapeutics Acquired by Sosei for up to $400m
In February 2015, Sosei acquired 100% of Heptares’ share capital for $180 million in cash consideration and up to $220 million contingent upon the successful progression of the company’s pipeline and platform.
Cheetah Medical announces study showing that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring
Cheetah Medical, a rapidly growing medical device company, announced today that a study by Duke University physicians, presented in a poster session at the recent ASA annual meeting, concluded that more than $3 of costs can be avoided by hospitals for every $1 they spend during surgery by using noninvasive hemodynamic monitoring.
AccuVein Announces Record Year with More Than 40 Percent Growth in Domestic Sales
AccuVein Inc. have announced that domestic sales grew over 40% year over year. This sales growth was achieved through a combination of new customers who have embraced the Company’s innovative AV400 vein visualization technology and existing customers who are ordering additional devices.